Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (TWST) highlights a critical need for innovative enterprise storage technologies, according to a new white paper. Key points include:

• Projected storage demand could exceed 25 zettabytes by 2030, outpacing available capacity.
• Approximately 75% of stored data is 'cold', rarely accessed, and likely never deleted.
• DNA data storage is proposed as a solution, promising high density, cost efficiency, and sustainability.

The company aims to lead in this space, addressing a projected $7 billion unmet storage demand.

Twist Bioscience Corporation (NASDAQ: TWST) and Biotia, Inc. have received an expanded Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This authorization enhances COVID-19 patient management by allowing for the identification of specific genomic mutations and viral lineages. Originally developed in 2020 and authorized in March 2021, the assay provides crucial insights into evolving variants like Omicron. The assay’s hybridization capture-based method improves mutation detection, aiding clinicians in treatment decisions.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CFO Jim Thorburn and CCO Patrick Finn will host a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Summit on August 9 at 2:00 p.m. PT in Dana Point, California. The event will be webcast live, and a replay will be available for 30 days post-event. Twist Bioscience specializes in synthetic DNA manufacturing using its innovative silicon platform, offering products for various industries including healthcare and agriculture.

Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2022 third quarter results on August 5, 2022, before market opening. A conference call will follow at 8:00 a.m. ET for analysts and investors to discuss the results and provide business updates. Twist, known for its innovative synthetic DNA manufacturing on silicon chips, continues to expand its offerings, including synthetic genes and tools for next-generation sequencing. Financial results will be posted on their website prior to the call.

Twist Bioscience Corporation (NASDAQ: TWST) has launched synthetic DNA controls for the human monkeypox virus, enhancing its portfolio of next-generation sequencing (NGS) applications for viral diseases. These controls, based on two known clades of the monkeypox virus, will improve the quality and validation of NGS and PCR assays. Twist's synthetic DNA controls cover over 80% of the viral genome and facilitate research and diagnostic tests. The new products align with the company’s commitment to addressing emerging public health concerns.

Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with DNAnexus to integrate their platforms, enhancing the design, validation, and commercialization of NGS-based diagnostic tests. This partnership enables Twist customers to utilize DNAnexus' cloud-based biomedical data analysis tools alongside Twist’s NGS Methylation Detection and Unique Molecular Identifier Adapter Systems. The collaboration aims to streamline data analysis, ultimately accelerating research in rare diseases and cancer diagnostics.

Twist Bioscience Corporation has announced the opening of its new facility in Quincy, Massachusetts, enhancing its in vivo antibody discovery capacity. This growth aligns with their strategy to accelerate antibody discovery for biopharma partners. The Twist Boston location, previously acquired in November 2021, is equipped with advanced tools, including four Berkeley Lights Beacon® Optofluidic Platforms, aimed at increasing screening capacity. The company plans to further expand its site to support future growth in biologics and diagnostics.

Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Ildong Pharmaceutical to license a suite of VHH antibody libraries for immuno-oncology applications. The agreement, marking Twist's first collaboration with a South Korean company, includes an upfront payment, annual fees, and royalties on product sales. The VHH libraries, known for their small size and versatility, enable the development of novel therapies targeting various diseases. This partnership aims to enhance Ildong's pipeline and supports Twist's strategic expansion in the Asia-Pacific region.

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, Senior VP of Business Development for Data Storage, will present at the Fujifilm 12th Annual Global IT Executive Summit in San Diego, CA, from June 22-25, 2022. Hellmold's presentation, titled "Scaling up from Data Lakes to Data Oceans," is scheduled for June 23, 3:15-3:45 PM PT. The summit focuses on data management trends and how DNA data storage can address exponential data growth. Twist Bioscience leverages a proprietary DNA synthesis platform for various applications across industries, including healthcare and agriculture.